| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $11,902,801 | 19 | 100 |
| RALLIS CHRIS A | director | 0 | $0 | 1 | $58,756 | $-58,756 |
| Sayad Pierre Sargis | Chief Medical Officer | 0 | $0 | 1 | $146,160 | $-146,160 |
| Brughera Marco Maria | director | 0 | $0 | 1 | $159,958 | $-159,958 |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 0 | $0 | 1 | $883,500 | $-883,500 |
| Raykov Rosty | director | 0 | $0 | 11 | $948,754 | $-948,754 |
| Southpoint Capital Advisors LP | 10 percent owner | 0 | $0 | 4 | $9.71M | $-9.71M |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated …
Over the last 12 months, insiders at Fennec Pharmaceuticals Inc. have bought $0 and sold $11.9M worth of Fennec Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Fennec Pharmaceuticals Inc. have bought $52,301 and sold $4.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,965 shares for transaction amount of $97,615 was made by Hackman Jeffrey S. (Chief Executive Officer) on 2025‑05‑19.
| 2026-09-15 | Sale | Brughera Marco Maria | director | 15,545 0.0433% | $10.29 | $159,958 | -0.85% | |
| 2026-09-01 | Sale | Raykov Rosty | Former Director | 10,000 0.029% | $12.11 | $121,100 | -11.72% | |
| 2026-08-31 | Sale | Sayad Pierre Sargis | Chief Medical Officer | 12,000 0.0343% | $12.18 | $146,160 | -14.01% | |
| 2026-08-27 | Sale | Andrade Robert | CHIEF FINANCIAL OFFICER | 75,000 0.2161% | $11.78 | $883,500 | -9.69% | |
| 2026-08-03 | Sale | Raykov Rosty | Former Director | 10,000 0.0291% | $9.58 | $95,800 | +12.41% | |
| 2026-07-01 | Sale | Raykov Rosty | Former Director | 9,599 0.0338% | $10.41 | $99,926 | +2.80% | |
| 2026-06-01 | Sale | Raykov Rosty | director | 9,747 0.0332% | $9.62 | $93,766 | +6.78% | |
| 2026-05-11 | Sale | RALLIS CHRIS A | director | 8,346 0.029% | $7.04 | $58,756 | +47.54% | |
| 2026-05-01 | Sale | Raykov Rosty | director | 10,781 0.039% | $6.47 | $69,753 | +58.95% | |
| 2026-04-01 | Sale | Raykov Rosty | director | 10,946 0.0377% | $6.31 | $69,069 | +60.69% | |
| 2026-03-02 | Sale | Raykov Rosty | director | 10,079 0.036% | $8.36 | $84,260 | +21.53% | |
| 2026-02-02 | Sale | Raykov Rosty | director | 10,349 0.0372% | $7.76 | $80,308 | +26.50% | |
| 2026-01-02 | Sale | Raykov Rosty | director | 10,312 0.0369% | $7.60 | $78,371 | +24.74% | |
| 2025-12-24 | Sale | Southpoint Capital Advisors LP | 10 percent owner | 1M 3.5493% | $7.50 | $7.5M | +20.47% | |
| 2025-12-05 | Sale | Raykov Rosty | director | 10,000 0.0362% | $7.54 | $75,400 | +19.01% | |
| 2025-11-18 | Sale | Southpoint Capital Advisors LP | 10 percent owner | 19,341 0.0705% | $8.79 | $170,048 | +1.26% | |
| 2025-11-17 | Sale | Southpoint Capital Advisors LP | 10 percent owner | 85,918 0.3133% | $8.79 | $755,193 | +1.14% | |
| 2025-11-14 | Sale | Southpoint Capital Advisors LP | 10 percent owner | 160,100 0.606% | $8.00 | $1.28M | +12.15% | |
| 2025-11-05 | Sale | Raykov Rosty | director | 10,000 0.036% | $8.10 | $81,000 | +6.06% | |
| 2025-10-10 | Sale | RALLIS CHRIS A | director | 1,775 0.007% | $9.24 | $16,401 | -1.63% |
| Southpoint Capital Advisors LP | 10 percent owner | 2744741 7.8271% | $29.37M | 3 | 8 | +14.67% |
| Andrade Robert | CHIEF FINANCIAL OFFICER | 217675 0.6207% | $2.33M | 1 | 11 | |
| Raykov Rosty | Former Director | 124411 0.3548% | $1.33M | 1 | 39 | |
| Butts Robert W | 41504000 118.3558% | $444.09M | 1 | 0 | ||
| Essetifin SPA | 10 percent owner | 3993694 11.3887% | $42.73M | 2 | 0 | +12.47% |
| MANCHESTER MANAGEMENT CO LLC | 10 percent owner | 2017357 5.7528% | $21.59M | 42 | 0 | |
| MANCHESTER MANAGEMENT PR, LLC | 10 percent owner | 1250000 3.5646% | $13.38M | 37 | 16 | <0.0001% |
| Hackman Jeffrey S. | Chief Executive Officer | 15000 0.0428% | $160,500.00 | 2 | 0 | +11.48% |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$22,020,194 | 25 | 38.25% | $405.58M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$57,263,116 | 11 | -8.37% | $386.95M |
| Increased Positions | 45 | +50% | 4M | +26.52% |
| Decreased Positions | 32 | -35.56% | 2M | -14.45% |
| New Positions | 20 | New | 1M | New |
| Sold Out Positions | 8 | Sold Out | 568,026 | Sold Out |
| Total Postitions | 103 | +14.44% | 16M | +12.07% |
| Southpoint Capital Advisors Lp | $31,313.00 | 12.36% | 4.08M | 0 | 0% | 2025-09-30 |
| Solas Capital Management, Llc | $16,803.00 | 6.63% | 2.19M | -45,000 | -2.02% | 2025-09-30 |
| Rosalind Advisors, Inc. | $15,950.00 | 6.29% | 2.08M | +31,196 | +1.52% | 2025-09-30 |
| Blackrock, Inc. | $9,307.00 | 3.67% | 1.21M | -14,631 | -1.19% | 2025-09-30 |
| Vanguard Group Inc | $7,340.00 | 2.9% | 955,764 | -11,328 | -1.17% | 2025-09-30 |
| Aigh Capital Management Llc | $5,234.00 | 2.07% | 681,501 | +229,101 | +50.64% | 2025-09-30 |
| State Street Corp | $2,620.00 | 1.03% | 341,201 | +4,707 | +1.4% | 2025-09-30 |
| Tang Capital Management Llc | $2,570.00 | 1.01% | 334,593 | +314,066 | +1,530.01% | 2025-09-30 |
| Geode Capital Management, Llc | $2,310.00 | 0.91% | 300,772 | -3,825 | -1.26% | 2025-09-30 |
| Morgan Stanley | $1,785.00 | 0.7% | 232,402 | -21,816 | -8.58% | 2025-09-30 |